Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
暂无分享,去创建一个
A. Whittemore | M. Beckmann | P. Fasching | R. Vierkant | A. Hein | J. Chang-Claude | B. Fridley | E. Goode | J. Hung | A. deFazio | D. Bowtell | B. Karlan | J. Benítez | D. Huntsman | P. Pharoah | M. Köbel | M. Jimenez-Linan | J. Brenton | B. Gilks | U. Menon | A. Ryan | A. Gentry-Maharaj | C. Karpinskyj | Naveena Singh | M. Widschwendter | G. Chenevix-Trench | S. Orsulic | M. Goodman | J. Lubiński | U. Eilber | A. Hartmann | Chen Wang | A. Osorio | R. Ness | T. Longacre | L. Kelemen | P. Sinn | E. Herpel | I. Campbell | K. Moysich | F. Modugno | D. Tiezzi | M. Ruebner | P. Ghatage | A. Jung | F. Taran | S. Brucker | A. Hartkopf | J. García-Donas | J. Lester | A. Magliocco | V. McGuire | J. Rothstein | W. Sieh | Raghwa N. Sharma | C. Kennedy | M. Block | S. Winham | B. Hernandez | A. Jensen | L. Cook | J. Gronwald | J. Palacios | J. Kelley | R. Edwards | E. Høgdall | S. Ramus | H. Steed | A. Chudecka-Głaz | K. Kalli | S. Johnatty | M. J. García | Z. Fogarty | P. Harnett | A. Staebler | Philipp Wagner | M. Intermaggio | O. Oszurek | S. Kommoss | J. Menkiszak | J. M. de Andrade | S. K. Kjaer | S. Deen | F. J. Candido dos Reis | D. Wachter | J. Alsop | J. Koziak | A. Tołoczko | Y. Natanzon | Zheng Li | P. Rambau | B. Gao | G. Nelson | J. Nation | Bryan M. McCauley | Wenqian Chen | L. Robles-Díaz | C. B. de Sousa | Aliecia L. Bouligny | Bryan M McCauley | N. Singh | Chang-Claude Jenny | M. García | Zachary C. Fogarty | R. Edwards | A. Ryan
[1] Evaluation of tumor infiltrating lymphocytes in breast cancer , 2018 .
[2] T. Sellers,et al. Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions , 2017, Cancer Epidemiology, Biomarkers & Prevention.
[3] Kconfab Investigators,et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer , 2017 .
[4] J. Schildkraut,et al. Ovarian cancer epidemiology in the era of collaborative team science , 2017, Cancer Causes & Control.
[5] J. Schorge,et al. Trends in the Use of Neoadjuvant Chemotherapy for Advanced Ovarian Cancer in the United States , 2017 .
[6] C. Genestie,et al. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC) , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Lara E Sucheston-Campbell,et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer , 2017, Nature Genetics.
[8] A. Jemal,et al. Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.
[9] Carsten Denkert,et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group , 2016, Modern Pathology.
[10] D. Tritchler,et al. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Köbel,et al. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype‐specific Lynch syndrome screening in ovarian carcinomas , 2016, Histopathology.
[12] S. Leung,et al. An Immunohistochemical Algorithm for Ovarian Carcinoma Typing , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[13] Nicolai J. Birkbak,et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.
[14] A. Reuss,et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. , 2016, Gynecologic oncology.
[15] Preetha Ramalingam,et al. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer. , 2016, Oncology.
[16] Lauren L. Ritterhouse,et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer , 2016, Oncotarget.
[17] B. Nelson,et al. Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer , 2016, Clinical Cancer Research.
[18] S. Mabuchi,et al. Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives , 2016, Journal of gynecologic oncology.
[19] Evaluation of tumor-infiltrating lymphocytes in breast cancer; proposal of a simpler method. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] K. Yamaguchi,et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Gourley,et al. Low-grade epithelial ovarian cancer: a number of distinct clinical entities? , 2015, Current opinion in oncology.
[22] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[23] A. Whittemore,et al. Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer , 2014, Clinical Cancer Research.
[24] M. Beckmann,et al. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study , 2014, British Journal of Cancer.
[25] J. George,et al. Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver , 2014, Clinical Cancer Research.
[26] E. Goode,et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. , 2014, Journal of the National Cancer Institute.
[27] M. Köbel,et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry , 2014, Histopathology.
[28] L. Meng,et al. The Role of BRCA Status on the Prognosis of Patients with Epithelial Ovarian Cancer: A Systematic Review of the Literature with a Meta-Analysis , 2014, PloS one.
[29] R. Kurman. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] Claudia C. Preston,et al. The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer , 2013, PloS one.
[31] A. Whittemore,et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. , 2013, The Lancet. Oncology.
[32] R. Bristow,et al. Survival in Women With Grade 1 Serous Ovarian Carcinoma , 2013, Obstetrics and gynecology.
[33] Francesmary Modugno,et al. Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[34] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[35] Peter Cresswell,et al. Pathways of antigen processing. , 2013, Annual review of immunology.
[36] Stefan Michiels,et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] R. Berkowitz,et al. Endometriosis-Associated Ovarian Cancer: A Review of Pathogenesis , 2013, International journal of molecular sciences.
[38] K. Cibulskis,et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.
[39] Carsten Denkert,et al. Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization , 2012, PloS one.
[40] F. Marincola,et al. Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.
[41] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[42] G. Coukos,et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. , 2012, Gynecologic oncology.
[43] Gord Glendon,et al. Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .
[44] M. Köbel,et al. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. , 2011, The Lancet. Oncology.
[45] G. Kenter,et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.
[46] Wendy Frankel,et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. , 2009, Archives of pathology & laboratory medicine.
[47] Matt van de Rijn,et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss , 2009, Modern Pathology.
[48] R. Berkowitz,et al. Increased HLA-DMB Expression in the Tumor Epithelium Is Associated with Increased CTL Infiltration and Improved Prognosis in Advanced-Stage Serous Ovarian Cancer , 2008, Clinical Cancer Research.
[49] S. Leung,et al. Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.
[50] R. Tothill,et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.
[51] Soldano Ferrone,et al. HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma , 2008, Clinical Cancer Research.
[52] I. Šteiner,et al. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. , 2008, Gynecologic oncology.
[53] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[54] D G Altman,et al. REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British journal of cancer.
[55] George Coukos,et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.
[56] Paul H. C. Eilers,et al. Flexible smoothing with B-splines and penalties , 1996 .